| Entries |
| Document | Title | Date |
|---|
| 20080213177 | Nanoparticles Comprising Rna Ligands - Materials and methods are provided for making nanoparticles having a core including metal and/or semiconductor atoms, which core is covalently linked to a plurality of ligands comprising a RNA ligand. The RNA ligands may include siRNA or miRNA. Also provided are uses of these nanoparticles in therapy and diagnosis. | 09-04-2008 |
| 20080292550 | Fluorinated 3'-Deoxythymidine Derivatives, a Method for Their Preparation and Their Use - The invention relates to new side chain-fluorinated 3′-deoxythymidine derivatives of the general formula I | 11-27-2008 |
| 20090010844 | Imaging Infection With Compounds That Bind to Thymidine Kinase - The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection. | 01-08-2009 |
| 20090016958 | Nucleoside based proliferation imaging markers - Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute into the effective tissue; and c) imaging the tissue, wherein an increase in binding of the compound to tissue compared to a normal control level of binding indicates that the mammal is suffering from a disease involving cellular proliferation. | 01-15-2009 |
| 20090047214 | Novel methylation marker - A method for predicting the likelihood of successful treatment of cancer with a topoisomerase inhibitor and/or a DNA damaging agent and/or a DNA methyltransferase inhibitor and/or a HDAC inhibitor comprises the steps of: | 02-19-2009 |
| 20090053137 | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof - The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and a metal coordinating moiety comprising a substituted phenyl, pyridyl, or pyrimidyl derivative. | 02-26-2009 |
| 20090136422 | Radioactive Surface Source and a Method for Producing the Same - A method for preparing a radioactive surface source for radiotherapy is disclosed. The method comprises: (a) providing a structure having a surface; (b) positioning the structure in a flux of at least one radionuclide so as to collect atoms of the at least one radionuclide on or beneath the surface; and (c) treating the surface such that the atoms are intercalated into the surface but allowed to recoil out of the surface upon radioactive decay. In various exemplary embodiments of the invention the method further comprises coating the surface by at least one layer of polymeric material, such that the atoms are collected into the polymeric material. | 05-28-2009 |
| 20090162281 | Radionuclide labeling of Vitamin B12 and Co-enzymes thereof - A compound useful for in vivo imaging of organs and tumors is provided of formula: | 06-25-2009 |
| 20090162282 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS - The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A | 06-25-2009 |
| 20090169474 | METHOD FOR NONINVASNELY AND QUANTITATIVELY MONITORING THERAPEUTIC AND DIAGNOSTIC TRANSGENE EXPRESSION INDUCED BY EX VNO AND IN VNO GENE TARGETING IN ORGANS, TISSUES AND CELLS - An composition in a method for noninvasively monitoring the expression of therapeutic transgene delivered ex vivo and in vivo for the treatment of diseases includes the step of quantitatively imaging a reporter gene expression which is coupled to a therapeutic gene on a plasmid vector to infer levels, location, or duration of the therapeutic gene expression in the targeted tissues or organs. The reporter gene is imaged using a radiopharmaceutical for scintigraphic imaging of the gene expression interactions with the reporter gene, namely positron emission tomography, gamma camera or single-photon emission computed tomography. The genes are delivered with a liposome encapsulated reporter-therapeutic linked transgene vector with balanced reporter/therapeutic transgene expression. A transgene composition includes the reporter gene linked to the therapeutic gene or genes incorporated in and delivered by a liposome encapsulated reporter-therapeutic linked transgene vector. | 07-02-2009 |
| 20090175787 | USE OF FRUCTOSE-BASED COMPOUNDS FOR THE DIAGNOSIS OF CANCER - This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer. Cancer cells have shown a higher level of fructose utilization as compared to glucose. Further, cancer cells have shown a preferential use of fructose for nucleic acid synthesis. The present invention takes advantage of these features and provides for fructose or fructose-based compositions for the diagnosis of cancer using imaging techniques such as positron emission tomography. | 07-09-2009 |
| 20090214425 | TUMOR THERAPY WITH REPLICATION COMPETENT SINDBIS VIRAL VECTORS - Disclosed herein are methods for treating a mammal harboring a solid tumor which expresses higher levels of High Affinity Laminin Receptors (LAMR) than normal cells of the same lineage comprising systematically administering to a mammal in need of such treatment a therapeutically effective amount of a Replication Competent (RC) Sindbis virus vector, wherein said vector encodes a suicide gene. | 08-27-2009 |
| 20090232735 | USE OF FRUCTOSE-BASED THERAPIES FOR THE TREATMENT OF CANCER - The methods and compositions of the invention are based on the preferential utilization of fructose by cancer cells. This invention relates to compositions, methods and kits utilizing fructose and other monosaccharides for the treatment of cancer. This invention also relates to methods and kits for using compositions to mimic or corrupt metabolic pathways of fructose and/or signal transduction pathways related to cancer cells for the treatment of cancer. | 09-17-2009 |
| 20090280059 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | 11-12-2009 |
| 20090285755 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY - The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule. | 11-19-2009 |
| 20090304587 | BIODEGRADABLE COMPOSITE FOR INTERNAL LOCAL RADIOTHERAPY - The present invention discloses composites which generally comprise a polymeric matrix and a hydrophobic organic compound which is associated with a radioisotope. The composites are biocompatible and biodegradable hydrogels suitable for use in internal local radiation therapy | 12-10-2009 |
| 20100008856 | TRACERS FOR MONITORING THE ACTIVITY OF SODIUM/GLUCOSE COTRANSPORTERS IN HEALTH AND DISEASE - Radiolabeled tracers for sodium/glucose cotransporters (SGLTs), their synthesis, and their use are provided. The tracers are methyl or ethyl pyranosides having an equatorial hydroxyl group at carbon-2 and a C1 preferred conformation, radio-labeled with | 01-14-2010 |
| 20100015052 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS - The invention relates to a method for improving stability of radiopharmaceutical precursors, and in particular non radiolabelled nucleoside derivatives which are used as precursors for production of radiolabelled nucleoside derivatives for use in in vivo imaging procedures such as positron emission tomography (PET). The invention further includes formulations of radiopharmaceutical precursors, and cassettes for automated synthesis apparatus comprising the same. | 01-21-2010 |
| 20100111860 | Radioactive material containing chitosan for inhibiting cancer and preparation method thereof - A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such as | 05-06-2010 |
| 20100111861 | DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO - A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject. | 05-06-2010 |
| 20100150835 | Synthesis of [18F] Fluoromethyl Benzene Using Benzyl Pentafluorobenzenesulfonate - The present invention discloses the reactivity of ponytail (“PT”) sulfonates as leaving groups in nucleophilic fluorination reactions. The results showed that using a pentafluorobenzenesulfonate precursor is a suitable leaving group for n. c. a. nucleophilic | 06-17-2010 |
| 20100183512 | USE OF CTHRC1 IN DIAGNOSING CANCER OF LIVER - Use of protein CTHRC1 or its nucleic acid in preparation for reagents or kits for diagnosing cancer of liver, the method for diagnosing cancer of liver by using the nucleic acid of CTHRC1, kit comprising the antibody to CTHRC1 or nucleic acid probe specific for the CTHRC1 protein and label, and the method for detecting the specific expression of protein CTHRC1 are disclosed. | 07-22-2010 |
| 20100196272 | COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN - The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce | 08-05-2010 |
| 20100196273 | NOVEL AGENT FOR IN VIVO PET IMAGING OF TUMOR PROLIFERATION - Compounds for in vivo diagnostic imaging of cellular proliferation are provided. The compounds include L-nucleosides such as a 2′-deoxy-2′-fluoro-L-ara-binofuranosyl pyrimidine nucleoside analogue. These nucleosides are labeled with a positron emitting radioisotope. The present invention also provides a method for in vivo diagnostic imaging of cellular proliferation. | 08-05-2010 |
| 20100254901 | Compositions comprising nucleic acid aptamers - Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds. | 10-07-2010 |
| 20100254902 | STABILIZATION OF RADIOPHARMACEUTICALS - The invention relates to stabilised radiopharmaceutical compositions which comprise: (i) an | 10-07-2010 |
| 20100272645 | MYOCARDIAL PERFUSION IMAGING METHOD - A myocardial imaging method that is accomplished by administering one or more adenosine A | 10-28-2010 |
| 20100290988 | FLUORINATED FRUCTOSE DERIVATIVES FOR PET IMAGING - The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies. | 11-18-2010 |
| 20100290989 | COMPOSITIONS AFFECTING HYALURONIC ACID MEDIATED ACTIVITY - Compositions comprising hyaluronic acid (HA) or agents that interfere with HA binding of HA receptors and methods of using the same are provided. For example, there is provided a composition comprising HA oligomers ranging in size from 10-mer to 80-mer and use of the same for promoting migration, growth or survival of wild-type or transformed/cancerous cells. There is also provided a composition comprising an agent that interferes with binding between an HA oligomer of a size of about 10-mer to about 80-mer and an HA receptor. Such compositions may be useful for therapeutic, diagnostic or imaging applications. Examples of therapeutic use are wound repair or cancer treatment. | 11-18-2010 |
| 20100290990 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF - The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope | 11-18-2010 |
| 20100322858 | Radiohaloimatinibs and Methods of Their Synthesis and Use in PET Imaging of Cancers - We disclose methods of synthesizing radiohalidated organic compounds and their use in positron emission tomography (PET) imaging of cancer cells. | 12-23-2010 |
| 20110002849 | THERAPY SELECTION METHOD - The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo. | 01-06-2011 |
| 20110059014 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS - Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. | 03-10-2011 |
| 20110070158 | Quality Control Module for Biomarker Generator System - A sample card and automated quality control module for a radiopharmaceutical synthesis system for conducting quality control tests on approximately one (1) unit dose of a radiopharmaceutical biomarker for use in positron emission tomography. The sample card and quality control module allow operators to conduct quality control tests in reduced time using micro-scale test samples from the radiopharmaceutical solution. The sample card works in conjunction with a microfluidic radiopharmaceutical synthesis system to collect samples of radiopharmaceutical solution on the scale of 5-20 microliters per sample. The sample card then interacts with the quality control module to feed the samples into a number of test vessels, where the samples undergo a number of automated quality control tests. | 03-24-2011 |
| 20110070159 | COMPOSITIONS COMPRISING RED MICROALGAE POLYSACCHARIDES AND METALS - Provided is a composition which contains a red microalga polysaccharide and a heavy metal, which is used as a cosmetic, diagnostic, or pharmaceutical formulation. The pharmaceutical formulation may be employed topically or for treating nutritional and other disorders. | 03-24-2011 |
| 20110081293 | METHODS AND COMPOSITIONS RELATED TO CLOT-BINDING LIPID COMPOUNDS - Disclosed are compositions and methods related to clot-binding head groups. The disclosed targeting is useful for treatment of cancer and other diseases and disorders. | 04-07-2011 |
| 20110117016 | DIAGNOSTIC COMPOUNDS - The Invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes. | 05-19-2011 |
| 20110142756 | Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer - The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types. | 06-16-2011 |
| 20110158906 | TARGETED BLOCK COPOLYMER MICELLES - The present invention provides a micelle comprising an amphiphilic block copolymer, said amphiphilic block copolymer consisting of (a) a hydrophobic polymer attached to the 5′ end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 5′ end of said second nucleic acid molecule; and/or (b) a hydrophobic polymer attached to the 3′ end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 3′ end of said second nucleic acid molecule. | 06-30-2011 |
| 20110176998 | IMAGING AND THERAPY OF VIRUS-ASSOCIATED TUMORS - The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection. | 07-21-2011 |
| 20110189088 | RADIOPHARMACEUTICAL COMPLEXES - The invention provides compounds such as chelating agents useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications. | 08-04-2011 |
| 20110250134 | SUSTAINED RELEASE NITRIC OXIDE FROM LONG LIVED CIRCULATING NANOPARTICLES - The invention provides methods for delivering a NO molecule or precursor thereof to a vascular compartment of a subject comprising: administering to the subject, a NO particle formulation, via an intravascular, intraperitoneal, or intramuscular administration, in an amount sufficient to induce vascular smooth muscle relaxation thereby delivering the NO molecule or precursor thereof to the vascular compartment of the subject, wherein the NO particle formulation comprises NO attached to a nanoparticle or microparticle. | 10-13-2011 |
| 20120020883 | Methods and compositions for detection of bacteria and treatment of diseases and disorders - Described herein are methods for detecting a bacteria in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using bacteria. The methods can be used in conjunction with methods for treating a disease, disorder or condition. Such sites, diseases and disorders include sites of cellular proliferation, such as tumors, tumor tissues, metastases, areas of inflammation, immunoprivileged sites or tissues, wounds and infections. Further described are bacteria for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a bacterium. Bacteria described herein include those that bind, sequester or accumulate radiolabeled compounds by expression of an endogenous gene product that binds to the radiolabeled compound. Additional imaging and therapeutic agents and methods also are described. | 01-26-2012 |
| 20120070373 | METHOD AND COMPOUND FOR TREATMENT OF CANCER USING PHOSPHOROUS-32 LABELED DNA - This invention provides a combination of a gene and isotope therapy that is applied to a cancerous tissue to selectively kill that associated cancer cells with minimal negative effects on surrounding non-cancerous cells. Functionally, the specific DNA fragments with labeled isotope are able to bind the tumor cells DNA through recombination, and then the isotope kills the tumor cells. A gene is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. Unlike traditional gene therapy, which employs a gene to express a protein, which can suppress the cancer cell growth or increase the sensitivity for radiation therapy or chemotherapy, the illustrative embodiment actually binds the radioactive substance via a gene. The illustrative embodiment produces the compound/agent containing a gene (DNA fragment) and P-32 through use of conventional P-32 labeling techniques such as those employed in molecular biology experiments (for example experiments used to test gene expression and gene amplification potency). In the illustrative embodiment, however, the same P-32 labeled DNA is employed directly for cancer treatment through a novel medical treatment method. Appropriate doses are provided to patients as part of a medical treatment method. | 03-22-2012 |
| 20120093725 | Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies - The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis. | 04-19-2012 |
| 20120114558 | APTAMER-MEDIATED DRUG RELEASE - The present invention relates to aptamer/drug conjugate complexes and the use of such complexes, together with a trigger compound, to inducibly release a drug. Through these complexes, the present invention provides a means for establishing a drug reservoir in a subject, whereby drug may be released as needed. One specific embodiment of the invention provides an aptamer/insulin conjugate complex from which insulin may be released by an innocuous, orally administrable trigger, such as quinine. | 05-10-2012 |
| 20120189544 | GASTROINTESTINAL DISEASE OR DISORDER IMAGING AND TREATMENT - The disclosure provides methods for detection, prognosis and diagnosis of gastrointestinal polyps, cancer diseases and disorders. | 07-26-2012 |
| 20120213701 | METHODS FOR TUMOR DIAGNOSIS AND THERAPY - The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule. | 08-23-2012 |
| 20120258043 | Linkable Lewis X Analogs - Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLe | 10-11-2012 |
| 20120269725 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER - Method of using androgen receptor and/or butyrylcholinesterase targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for the treatment and diagnosis of cancer. | 10-25-2012 |
| 20120276005 | CONJUGATES FOR DUAL IMAGING AND RADIOCHEMOTHERAPY: COMPOSITION, MANUFACTURING, AND APPLICATIONS - Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X | 11-01-2012 |
| 20130064767 | IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE - The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection. | 03-14-2013 |
| 20130071326 | UNIVERSAL CELL-DIRECTED THERANOSTICS - The present invention provides modified stem cells that comprise a delivery system that comprises at least one microparticle or nanoparticle, wherein the at least one microparticle or nanoparticle comprises an active agent. The present invention also provides delivery methods that comprise the administration of the modified stem cells to a subject. Additional aspects of the present invention pertain to methods of making said modified stem cells. | 03-21-2013 |
| 20130078184 | FLUORINATED FRUCTOSE DERIVATIVES FOR PET IMAGING - The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies. | 03-28-2013 |
| 20130101506 | COMPOSITIONS COMPRISING NUCLEIC ACID APTAMERS - Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds. | 04-25-2013 |
| 20130149242 | Labeled Alginate Conjugates for Molecular Imaging Applications - Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents. | 06-13-2013 |
| 20130156698 | TISSUE TARGETING - Methods and compositions related to targeting agents to tumor tissue are described. | 06-20-2013 |
| 20130183238 | Formulation, Apparatus and Method for Stabilizing Radiopharmaceuticals - A formulation for stabilizing a radiopharmaceutical. The formulation includes a radiopharmaceutical (or a pharmaceutically acceptable salt thereof), a gas which has oxygen, a stabilizer, and a solvent. | 07-18-2013 |
| 20130195757 | SPARC BINDING APTAMERS AND USES THEREOF - The invention relates to nucleic acid aptamers having the ability to bind human SPARC protein (osteonectin) with specificity. The invention also relates to compositions including such aptamers, as well as methods of identifying such aptamers. The invention further relates to methods for using such aptamers in treating and diagnosing proliferative diseases such as, e.g., cancer. | 08-01-2013 |
| 20130224113 | IMAGING DIAGNOSTICS BY COMBINING CONTRAST AGENTS - The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation. | 08-29-2013 |
| 20130243692 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY - This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan. | 09-19-2013 |
| 20140023586 | COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN - The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce | 01-23-2014 |
| 20140044642 | RADIOPHARMACEUTICAL IMAGING OF NEURODEGENERATIVE DISEASES - Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein. | 02-13-2014 |
| 20140099262 | ISOTOPICALLY LABELED CDP-CHOLINE AND USES THEREOF - The present invention provides CDP-Choline (Citicoline) and any salt thereof comprising at least one isotopically labeled carbon atom directly bonded to at least one deuterium atom, a composition comprising said CDP-Choline, uses thereof, methods for diagnosing and evaluating a state, condition, or disease in a subject utilizing CDP-Choline of the invention and kits comprising CDP-Choline of the invention. | 04-10-2014 |
| 20140178303 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS - Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids). | 06-26-2014 |
| 20140186262 | NOVEL GALL BLADDER IMAGING AGENT AND ITS PREPARATION METHOD - A novel gall bladder image agent which includes a radio-labelled MAG3-tri-galactosamine, and its preparation method, which includes reacting mercaptoacetyltriglycine (MAG3)-tri-galactosamine, SnF2 and Tc-99m in the presence of a phosphate buffer solution (at pH of from 10.0˜12.0) to obtain Tc-99m-MAG3-tri-galactosamine, when the MAG3-tri-galactosamine is MAG3-DCM-Lys(Gah-GalNAc)3 (where DCM represents a dicarboxymethyl group, and Gah represents a glycine-aminohexyl group), it obtains a labelling yield of at least 90%, and its specific radioactivity is at least 7.0×109 Bq/mg. | 07-03-2014 |
| 20140193337 | 18F-SACCHARIDE-FOLATES - The present invention is directed towards new | 07-10-2014 |
| 20140219916 | METHOD AND COMPOUND FOR TREATMENT OF CANCER USING PHOSPHOROUS-32 LABELED DNA - This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. Linear DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. The illustrative embodiment produces the compound/agent containing a DNA fragment and P-32 through use of conventional P-32 labeling techniques such as those employed in molecular biology experiments (for example experiments used to test gene expression and gene amplification potency). The same P-32 labeled DNA can be employed directly for cancer treatment through a novel medical treatment method. Appropriate doses are provided to patients as part of a medical treatment method. | 08-07-2014 |
| 20140219917 | OLIGOSACCHARIDE CONJUGATES FOR TARGETING BACTERIA AND USES RELATED THERETO - This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic. | 08-07-2014 |
| 20140234216 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES - The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy. | 08-21-2014 |
| 20140234217 | REMOTE ASSEMBLY OF TARGETED NANOPARTICLES USING COMPLEMENTARY OLIGONUCLEOTIDE LINKERS - The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject. Components of the targeted delivery compositions are put together through duplex formation between oligonucleotides. | 08-21-2014 |
| 20140248212 | NON-IMMUNOGENIC POSITRON EMISSION TOMOGRAPHY REPORTER GENE SYSTEMS - Embodiments of the invention include a PET/SPECT reporter gene system that uses enhanced non-immunogenic versions of a human mitochondrial thymidine kinase 2 expressed in cytoplasm to preferentially trap novel PET/SPECT radiolabeled L and D-enantiomer analogs of the natural substrate thymidine. Such highly sensitive, non-immunogenic reporter genes function in combination with a set of novel, radiolabeled probes in whole body molecular imaging applications using positron emission tomography (PET) or single photon emission computed tomography (SPECT). | 09-04-2014 |
| 20140255307 | CONTRAST MEDIUM COMPOSITION AND METHOD OF BIO IMAGINATION USING THE SAME - The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment. | 09-11-2014 |
| 20140271470 | TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER - The present invention relates to methods of diagnosing and treating prostate cancer, including metastatic prostate cancer. Related pharmaceutical compositions are also provided. | 09-18-2014 |
| 20140314671 | PROBES AND METHODS OF IMAGING A BACTERIAL INFECTION - Embodiments of the present disclosure provide for labeled probes such as labeled maltose probes and labeled acarbose probes, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, kits for diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, and the like. | 10-23-2014 |
| 20150017098 | CARRIER THAT TARGETS FUCOSYLATED MOLECULE-PRODUCING CELLS - The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells. | 01-15-2015 |
| 20150023875 | System for Targeted Delivery of Therapeutic Agents - The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof. | 01-22-2015 |
| 20150023876 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSING AND TREATING CD206 EXPRESSING CELL-RELATED DISORDERS - A method of diagnosing a CD206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to CD206. A method of treating a CD206 expressing cell-related disorder is also provided, as well as an ex vivo method and kit for quantitating the number of cells expressing CD206 in a bodily fluid. | 01-22-2015 |
| 20150044136 | Ophthalmological treatment for michobial infections - The invention described herein relates to the composition of a liquid in which a silver ion moiety can act as a preservative as well as an astringent for the inhibition of microbial infections of the eye. | 02-12-2015 |
| 20150056136 | RADIOPHARMACEUTICAL SYNTHESIS METHODS - The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals. | 02-26-2015 |
| 20150118157 | Compounds and Methods of Making Compounds - Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in | 04-30-2015 |
| 20150132221 | METHODS FOR DIAGNOSING AND MONITORING EOSINOPHILIC ESOPHAGITIS - Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. | 05-14-2015 |
| 20150291647 | Compositions and Methods for 18F-Fluorodeoxyglycosylamines - Various compositions and methods for Quasi-Amadori products and derivatives thereof are contemplated in which a halogenated carbohydrate is reacted with a primary amino group of an affinity ligand. In especially preferred aspects, the Quasi-Amadori product is formed from 2-fluorodeoxyglucose and an affinity moiety that preferentially or selectively binds to a neural cell or neural structure. Where contemplated compounds include | 10-15-2015 |
| 20150367005 | METHOD OF SYNTHESIZING FLUORINE-18 LABELED RADIOPHARMACEUTICALS IN ETHANOL AND WATER - A method of preparing fluorine-18 labeled radiopharmaceuticals ( | 12-24-2015 |
| 20160000945 | METHODS FOR EVALUATING BRAIN-WIDE PARAVASCULAR PATHWAY FOR WASTE CLEARANCE FUNCTION AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS BASED THEREON - Methods are provided for measuring glio-vascular pathway (“glymphatic system”) function in the brain of a mammal which include performing imaging of the brain and measuring cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange in the brain. The methods can be used to track the exchange between CSF and ISF compartments. An imaging agent is optionally administered intrathecally. The imaging agent can be a negative or positive (paramagnetic) contrast agent and dynamic or contrast-enhanced magnetic resonance imaging (MRI) of the brain can be performed. The imaging agent can be a positron-emitting radionuclide tracer and positron emission tomography (PET) can be performed. Methods for treating diseases or disorders of the mammalian brain are also provided, in which the methods increase or decrease glymphatic clearance. | 01-07-2016 |
| 20160008496 | IMAGING DIAGNOSTICS BY COMBINING CONTRAST AGENTS | 01-14-2016 |
| 20160038597 | CARRIER THAT TARGETS FUCOSYLATED MOLECULE-PRODUCING CELLS - The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells. | 02-11-2016 |
| 20160058896 | METHOD AND COMPOUND FOR TREATMENT OF CANCER USING PHOSPHOROUS-32 LABELED DNA - This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. The mechanism of cancer cells uptake of large DNA fragment (larger than 30 bp) is endocytosis which does not occur in normal organ cells. We are the first to identify this difference and use the selectivity to deliver isotope P-32 to treat cancer. The DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. Appropriate doses are provided to patients as part of a medical treatment method. | 03-03-2016 |
| 20160074536 | SYSTEMS AND METHODS FOR INTRA-TARGET MICRODOSING (ITM) - Systems and methods for intra-target microdosing are disclosed. According to an aspect, a method for intra-target microdosing includes administering a microdose of drug into target tissue within a subject. The method also includes measuring efficacy of the administered drug to the target tissue. | 03-17-2016 |
| 20160083485 | THERAPEUTIC AND IMAGING COMPOSITIONS AND USES THEREOF - Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes various embodiments of the present invention. | 03-24-2016 |
| 20160184459 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE - The present invention provides a compound having the structure: | 06-30-2016 |
| 20160199500 | COMPOSITIONS COMPRISING VITAMIN B12 AND INTRINSIC FACTOR AND METHODS OF USE THEREOF | 07-14-2016 |
